8:38 AM
 | 
Jan 26, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Astellas/Vical CMV vaccine ASP0113 fails stem cell transplant trial

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the international Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients.

The company told BioCentury it does not plan to develop ASP0113 independently if Astellas terminates its exclusive, worldwide license to the candidate, which the pharma...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >